KALTF News and Press, Kalytera Therapeutics From 07/15/20

SAN FRANCISCO, July 15, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") announces that it has received conditional approval from the TSX Venture Exchange ( " TSXV ”) and partial revocation orders from the Briti...

SAN FRANCISCO, June 30, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today provided updates regarding the following three matters: (1) the delay in filing of its annual financial statements for the year ending Decem...

SAN FRANCISCO, June 16, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") announced today that it is working with Salzman Group toward completing definitive agreements for Kalytera’s acquisition of Salzman Group (...

SAN FRANCISCO, June 15, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today announced proof-of-concept data demonstrating that R-107 reduces tissue damage and increases survival in a lethal rodent model of chlorine i...

SAN FRANCISCO, June 09, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today announced new proof-of-concept data for R-107, its liquid nitric oxide donor, in treatment of pulmonary arterial hypertension ( “PAH&...

Kalytera Therapeutics ( OTC:KALTF +70.3% ) says R-107 readily converts in vivo into its active payload R-100, which accumulates and provides for a sustained release of nitric oxide into lung tissues. More news on: Kalytera Therapeutics Inc., Healthcare stocks news, Read more ...

SAN FRANCISCO, June 05, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today announced new in vivo data demonstrating that R-107 exhibits rapid conversion to its active payload R-100 in rats, followed by sustained rel...

SAN FRANCISCO, June 02, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today announced that Salzman Group, Inc. has filed a provisional patent application protecting the use of its proprietary, liquid, nitric oxide do...

SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the " Company " or " Kalytera ") today announced new proof-of-concept data demonstrating that R-107 reduces tissue damage and preserves organ function in a lethal rodent model of s...

SAN FRANCISCO, May 25, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today issued the following letter to shareholders from the Company’s President and CEO, Robert Farrell. Dear Kalytera Shareholders, I...